Picture Berlin Partner Top News Tacalyx Extends Seed Round to €14m 650x100px
Document › Details

Biotechpharma UAB. (4/16/19). "Press Release: Biotechpharma to Expand Process Development and GMP Manufacturing Capacity to 5,000L". Vilnius.

Region Region Vilnius
  Country Lithuania
Organisation Organisation Biotechpharma UAB
  Group Northway (Group)
Products Product contract manufacturing (biologicals)
  Product 2 biopharmaceutical
Persons Person Žunda, Giedrius (Northway 201812– CEO of Biotechpharma UAB before Sicor Biotech UAB/Teva since 2002)
  Person 2 Ternes, Frank (Northway 201810– CBO at Biotechpharma UAB before Rentschler + Boehringer Ingelheim)

Biotechpharma UAB will expand its existing manufacturing facility by adding a new line of bioreactors

Biotechpharma UAB, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced further expansion of its fermentation capacity to 5,000L along with an additional state of the art process development laboratory, investing more than €50 million in the expansion.

Dr. Vladas Bumelis, Chairman of the Board, stated, “The expansion comes amid growing global demand for flexible and responsive outsourcing partners that are able to support the full product lifecycle, from upstream and downstream process development and optimization to GMP manufacturing of drug substance and formulated drug product.” With the new capacity, Biotechpharma continues to advance its mission of becoming a single-source CDMO able to support its worldwide customers with a full range of development and manufacturing services to support clinical and commercial manufacturing.

“We are thrilled to announce this latest expansion of our infrastructure, as it will allow us to better support our customers’ biological development programs with quality, speed and flexibility of service,” said Giedrius Žunda, CEO of Biotechpharma.

The new plant in Europe, located at the company’s site in Vilnius, Lithuania, will contain a new line of bioreactors for microbial fermentation at 5,000L scale and the necessary equipment for downstream processing operations. Flexible facility design will also allow for increased mammalian cell culture production capacities in addition to the already existing two lines of 1000-L and 2000-L for mammalian cell production, both equipped with single use bioreactors. Completion of the plant, which should be operational in Q4 2020, will result in an increase in Biotechpharma’s volume capacity by nearly a factor of two.

“With this latest expansion and plans for continued growth, we are better positioned than ever to meet the growing global demand for these specialized capabilities – and to become a fully integrated biopharmaceutical CDMO.” Said Frank Ternes, CBO of Biotechpharma.

Record changed: 2023-06-05


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Northway (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px

» top